CSL Behring

Biotherapies for Life

CSL Behring is a global leader in the plasma protein biotherapeutics industry. We research, develop, manufacture and market biotherapies that are used to treat serious and rare conditions. Users of our therapies rely on them for their quality of life and, in many cases, for life itself.

Our commitment to saving lives and improving the quality of life for people with serious and rare conditions is evident in everything we do. Whether we are manufacturing and marketing safe and effective products or researching and developing innovative biotherapies, we are first and foremost focused on fulfilling our customers’ needs.

What are Biotherapies?

Our life-saving biotherapies are indicated for the treatment of serious and rare conditions. These conditions include coagulation (bleeding) disorders such as hemophilia and von Willebrand disease, immune deficiencies and genetic emphysema (inherited respiratory disease). Biotherapies are also used in critical care settings to treat shock, sepsis and severe burns, during cardiac surgery and for wound healing. In addition, biotherapies are used to prevent hemolytic disease in the newborn resulting from Rh factor incompatibilities.

Biotherapies differ from conventional chemical-derived pharmaceuticals in many ways. They are derived from human plasma, or produced as their recombinant equivalents, instead of from chemicals. These expensive source materials comprise a much higher portion of the therapy’s cost than the chemicals used in pills and tablets. Biotherapies also undergo rigorous safety controls and inspections throughout every step of the year-long manufacturing process, from the collection of plasma to the final packaging of the finished product.

While plasma therapeutics treat small patient populations, traditional pharmaceuticals may treat millions of patients worldwide. As a result, economies of scale in the plasma protein industry are much narrower than in the traditional pharmaceutical industry. In fact, the costs of production for plasma-derived medical therapies are typically around 70% of the selling price compared to only about 19% for chemical-based pharmaceuticals.

Our products are produced at facilities in Bern, Switzerland; Marburg, Germany; Kankakee, Illinois and Broadmeadows, Australia, in accordance with international safety and quality standards. The company also operates CSL Plasma, one of the world’s largest plasma collection networks throughout the United States and Germany. CSL Behring employs more than 9,000 people in 19 countries.

We are passionate about safety, quality and the customers we serve. Our extensive research and development and range of support services demonstrate our ongoing commitment to all people who rely on our products.

Not all products are available in every country. For specific information on products where you live, select your country from the drop-down box on our homepage.